Jim Cramer Explains Johnson & Johnson’s (JNJ) Shares Have Gained
Key takeaways
- Jim Cramer Explains Johnson & Johnson’s (JNJ) Shares Have Gained Ramish Cheema Mon, June 15, 2026 at 2:08 AM GMT+7 2 min read JNJ MRK SPCX We recently published
- Jim Cramer Didn’t Hold Back On Space X’s IPO & Discussed These 12 Stocks.
- “illiquidity =insane health care gains like Cardinal and JNJ”
Jim Cramer Explains Johnson & Johnson’s (JNJ) Shares Have Gained Ramish Cheema Mon, June 15, 2026 at 2:08 AM GMT+7 2 min read JNJ MRK SPCX We recently published
Jim Cramer Didn’t Hold Back On Space X’s IPO & Discussed These 12 Stocks. Johnson & Johnson (NYSE:JNJ) is one of the stocks discussed by Jim Cramer.
Johnson & Johnson (NYSE:JNJ)’s shares are up by 53% over the past year and by 15% year-to-date. Leerink Partners discussed the firm on May 13th as it upgraded the shares to Outperform from Market Perform and raised the share price target to $265 from $252. The financial firm commented that Johnson & Johnson (NYSE:JNJ)’s new drugs will inject momentum into the firm’s revenue growth and share price performance. Cramer has also discussed the firm’s drugs on several occasions over the past couple of months. For instance, in his Mad Money appearance on May 29th, the CNBC TV host compared Johnson & Johnson (NYSE:JNJ) to Merck and commented that “Merck’s cancer dominance has been challenged of late by JNJ.” In this tweet, he commented on the firm’s recent share price performance, which has seen Johnson & Johnson (NYSE:JNJ)’s shares gain 7.7% over the past month, in the context of illiquidity in the market: